Active Postlicensure Safety Surveillance for Recombinant Zoster Vaccine Using Electronic Health Record Data

Recombinant zoster vaccine (RZV) (Shingrix; GlaxoSmithKline, Brentford, United Kingdom) is an adjuvanted glycoprotein vaccine that was licensed in 2017 to prevent herpes zoster (shingles) and its complications in older adults. In this prospective, postlicensure Vaccine Safety Datalink study using el...

Descripción completa

Detalles Bibliográficos
Autores principales: Nelson, Jennifer C, Ulloa-Pérez, Ernesto, Yu, Onchee, Cook, Andrea J, Jackson, Michael L, Belongia, Edward A, Daley, Matthew F, Harpaz, Rafael, Kharbanda, Elyse O, Klein, Nicola P, Naleway, Allison L, Tseng, Hung-Fu, Weintraub, Eric S, Duffy, Jonathan, Yih, W Katherine, Jackson, Lisa A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Original Contribution
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9896469/
https://www.ncbi.nlm.nih.gov/pubmed/36193854
http://dx.doi.org/10.1093/aje/kwac170

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9896469/
https://www.ncbi.nlm.nih.gov/pubmed/36193854
http://dx.doi.org/10.1093/aje/kwac170

Ejemplares similares